China Personalized Medicine Market Size, Share, Trends and Forecast by Product, End Use, and Region, 2026-2034

China Personalized Medicine Market Summary:

The China personalized medicine market size reached USD 101.54 Million in 2025. The market is projected to reach USD 206.03 Million by 2034, growing at a CAGR of 8.18% during 2026-2034. The market is driven by robust government policy support through the 14th Five-Year Plan and strategic precision medicine initiatives, the rapid integration of artificial intelligence across drug discovery and diagnostic applications, and the expansion of digital health infrastructure including telemedicine platforms that enable personalized healthcare delivery at scale. These fundamental drivers are transforming China's healthcare landscape and expanding the China personalized medicine market share.

China Personalized Medicine Market Outlook (2026-2034):

The Chinese personalized medicine market is poised for sustained expansion as the government pushes forward precision medicine programs in the 14th Five-Year Plan. Increasing access to genomic sequencing and AI-based diagnostic platforms is predicted to further personalize treatment in oncology, rare diseases, and chronic diseases. Additionally, the countrywide deployment of 5G networks and unified electronic medical records will facilitate real-time data exchange across platforms, driving exhaustive patient profiling and more precise therapeutic intervention.

Impact of AI:

AI is reshaping China's personalized medicine space at its core through the power to deliver precision diagnosis, speeding up drug discovery timelines, and enabling personalized treatment planning. AI algorithms are being used to analyze medical images, delivering diagnostic accuracy rates of more than 90 percent in some use cases such as lung nodule detection and cancer screening. In drug development, AI platforms are identifying molecular interactions and therapeutic targets with high accuracy, slashing time and cost. In addition, digital health platforms powered by AI are now combining patient information, genomics, and symptom tracking to provide personalized treatment guidelines, ensuring that more tailored medicine is available and attainable across China's varied healthcare system.

Market Dynamics:

Key Market Trends & Growth Drivers:

Government Policy Support Driving Strategic Precision Medicine Development

The Chinese government has established personalized medicine as a national strategic priority through comprehensive policy frameworks that provide substantial funding, regulatory support, and infrastructure development. The 14th Five-Year Plan (2021-2025) continues to emphasize interdisciplinary research and the use of artificial intelligence for biological discovery and precision medicine applications. Since the introduction of the Precision Medicine Strategy in 2015, successive Five-Year Plans have significantly advanced the application of technologies such as genetic testing and pharmacogenomics in the personalized treatment of cancer and rare diseases. China’s precision medicine market has grown rapidly in recent years and is projected to maintain strong momentum through 2030. This sustained expansion underscores its rising importance as a key growth engine within the nation’s healthcare sector, driven by increasing investment, technological innovation, and government support for advanced medical research and personalized treatment development. The government has also designated biotechnology as a strategic emerging industry, providing preferential tax treatment, subsidies, and government procurement initiatives to foster innovation. These policies are creating a favorable ecosystem for domestic and international companies to develop and commercialize personalized medicine solutions, while regulatory reforms are accelerating approval processes for innovative diagnostics and therapeutics that enable targeted patient care.

Artificial Intelligence Integration Revolutionizing Drug Discovery and Clinical Diagnostics

The China personalized medicine market is witnessing strong growth driven by the rapid integration of artificial intelligence across the healthcare value chain—from early-stage drug discovery to clinical diagnosis and treatment planning. The country’s expanding “AI + Pharma” ecosystem reflects growing investment in platforms capable of analyzing large-scale biological data and predicting individualized therapeutic strategies. A leading example is Insilico Medicine, which advanced an AI-discovered drug candidate for idiopathic pulmonary fibrosis into Phase II clinical trials, showcasing AI’s transformative potential in accelerating precision drug development. In clinical diagnostics, AI is increasingly deployed in medical imaging to enhance diagnostic accuracy and efficiency across oncology, cardiology, and respiratory care. China’s National Medical Products Administration has approved numerous AI-based diagnostic tools under its highest classification, reinforcing the country’s commitment to intelligent healthcare innovation. Rapid adoption in areas such as cancer detection, pneumonia diagnosis, and cardiac assessment highlights AI’s growing clinical relevance. Strong policy support continues to drive AI integration in pharmaceutical research, enabling faster, safer, and more cost-effective drug development. This strategic alignment between AI innovation and precision medicine is positioning China as a major global leader in next-generation healthcare technologies.

Digital Health Infrastructure Expansion Enabling Scalable Personalized Healthcare Delivery

The rapid expansion of digital health infrastructure is reshaping the delivery of personalized medicine across China’s diverse regions. Telemedicine platforms and unified electronic medical record systems are enabling more connected and data-driven healthcare ecosystems. Leading digital health providers such as Ping An Good Doctor, Alibaba Health, JD Health, and WeDoctor are leveraging AI technologies, including natural language processing and machine learning, to deliver personalized, scalable healthcare services. These platforms increasingly integrate patient records, genomic data, and treatment histories to generate precise, data-informed recommendations. The rollout of 5G networks is further advancing real-time data transmission, supporting remote consultations and continuous monitoring in areas with limited medical resources. A notable milestone in this digital transformation was the launch of Tsinghua University’s AI Agent Hospital in 2025, featuring 42 AI doctors across 21 specialties and covering hundreds of diseases. This virtual hospital exemplifies China’s commitment to using AI to address physician shortages and expand healthcare access. Aligned with the 14th Five-Year Plan for National Health Informatization, China aims to achieve full digital connectivity across public health institutions by 2025. This integrated health information infrastructure provides the foundation for implementing personalized medicine, supporting real-time clinical decision-making and holistic patient care nationwide.

Key Market Challenges:

Data Privacy Protection and Cross-Border Collaboration Compliance Complexity

China's evolving data protection regulatory landscape presents significant challenges for researchers and healthcare providers working with sensitive genetic and health information required for personalized medicine applications. In 2021, China adopted the Personal Information Protection Law, which provides a comprehensive legal framework for protecting personal information, including sensitive medical health data. Despite offering critical legal safeguards for processing health data, further clarification is needed regarding specific issues, including the meaning of separate consent, cross-border data transfer requirements, and exceptions for scientific research. The processing of real-world data triggers patient privacy concerns and must adhere to relevant data laws and regulations, creating possible legal impediments for researchers conducting personalized medicine studies. Challenges such as disparities in regulatory frameworks, concerns regarding data privacy, and variations in healthcare systems can obstruct the smooth integration of genomic data into clinical practice. China faces hurdles related to data accessibility, quality, and ethical concerns amid swift technological progress. The need to balance personal information protection with the public value of large-scale health data analysis remains a practical problem requiring pragmatic regulatory solutions. These compliance challenges are particularly acute for international collaborations and multi-institutional research projects that require data sharing across organizational and geographic boundaries.

Regulatory Standardization Gaps and Biomarker Validation Inconsistencies

The regulatory framework for personalized medicine diagnostics and therapeutics in China remains fragmented despite significant progress, with inconsistent standards across different testing modalities and therapeutic approaches creating barriers to widespread clinical adoption. While the National Medical Products Administration has made strides in approving innovative medical devices and diagnostics, the lack of standardized protocols for biomarker discovery, validation, and clinical implementation complicates the development and commercialization process for personalized medicine solutions. Regulatory hurdles related to the lack of standardized protocols and regulatory frameworks for biomarker-based diagnostics and therapies can impede market growth and delay the introduction of innovative products. Chinese legislators' regulatory path for medical and health information protection is more abstract and generalized compared to mature markets, with protections for the general processing of medical and health information in AI scenarios being relatively weak. The current regulatory environment requires companies to navigate multiple overlapping regulations, including the Medical Devices Supervision Regulation, Data Security Law, Personal Information Protection Law, and Administrative Regulations on Human Genetic Resources, each with different requirements and enforcement mechanisms. This regulatory complexity increases compliance costs, extends approval timelines, and creates uncertainty for companies developing personalized medicine products.

Geographic Healthcare Infrastructure Disparities Limiting Equitable Access

Significant variations exist between urban and rural healthcare infrastructure in China, with advanced personalized medicine technologies and specialized services concentrated predominantly in major metropolitan areas, including Beijing, Shanghai, and Guangdong province. Limited access to specialized genetic testing facilities, advanced diagnostic equipment, and trained personnel in rural and remote regions creates substantial inequality in precision medicine availability and quality of care. This disparity is evident in the physician-to-population ratio, as China has only a fraction of the radiologists available in developed countries, severely limiting the capacity to implement imaging-based personalized diagnostics, particularly in underserved and rural regions. Regional economic differences further exacerbate these challenges, as personalized medicine diagnostics and therapeutics often carry higher costs than traditional approaches, making them less accessible to populations in lower-income regions. While telemedicine platforms and digital health initiatives are attempting to bridge these gaps through remote consultation and diagnostic services, connectivity issues in rural areas, particularly affecting nomadic and remote communities, hamper the consistent delivery of teleconsultations and transfer of medical information. Unless these geographic disparities are systematically addressed through targeted infrastructure investments and policy interventions, large segments of China's population risk being excluded from the benefits of personalized medicine advances.

China Personalized Medicine Market Report Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the China personalized medicine market, along with forecasts at the country and regional levels for 2026-2034. The market has been categorized based on product and end use.

Analysis by Product:

• Personalized Medicine Diagnostics
  • Genetic Testing
  • Direct-To-Consumer (DTC) Diagnostics
  • Esoteric Lab Services
  • Esoteric Lab Tests
• Personalized Medicine Therapeutics
  • Pharmaceutical
  • Genomic Medicine
  • Medical Devices
• Personalized Medical Care
  • Telemedicine
  • Health Information Technology
• Personalized Nutrition and Wellness
  • Retail Nutrition
  • Complementary and Alternative Medicine

The report has provided a detailed breakup and analysis of the market based on the product. This includes personalized medicine diagnostics (genetic testing, direct-to-consumer diagnostics, esoteric lab services, and esoteric lab tests), personalized medicine therapeutics (pharmaceutical, genomic medicine, and medical devices), personalized medical care (telemedicine and health information technology), and personalized nutrition and wellness (retail nutrition and complementary and alternative medicine).

Analysis by End Use:

• Hospitals
• Diagnostic Centers
• Research and Academic Institutes
• Others

A detailed breakup and analysis of the market based on the end use have also been provided in the report. This includes hospitals, diagnostic centers, research and academic institutes, and others.

Analysis by Region:

• North China
• East China
• South Central China
• Southwest China
• Northwest China
• Northeast China

The report has also provided a comprehensive analysis of all the major regional markets, which include North China, East China, South Central China, Southwest China, Northwest China, and Northeast China.

Competitive Landscape:

The China personalized medicine market is characterized by intense competition among domestic biotechnology leaders, international pharmaceutical companies, and emerging digital health platforms, each leveraging distinct competitive advantages to capture market share. Major domestic players, including BGI Genomics, Berry Genomics, and Annoroad Gene Technology, dominate the genetic testing and sequencing services segment, benefiting from government support, large-scale domestic patient populations, and cost-competitive service delivery. These companies have established strong positions through vertical integration strategies, controlling the value chain from sample collection to analysis and reporting. International pharmaceutical giants such as Roche, AstraZeneca, and Merck are focusing on developing and commercializing precision oncology therapeutics and companion diagnostics, often through strategic partnerships with Chinese companies to navigate regulatory requirements and distribution networks. Digital health platforms including Ping An Good Doctor, Alibaba Health, and JD Health are increasingly entering the personalized medicine space by integrating AI-powered diagnostic support, telemedicine services, and direct-to-consumer genetic testing offerings into their comprehensive healthcare ecosystems. Competition is also intensifying around AI-enabled clinical decision support systems, with technology companies and research institutions developing sophisticated algorithms for image analysis, treatment optimization, and predictive modeling to support personalized treatment planning.

China Personalized Medicine Market Industry Latest Developments:

• May 2025: Tsinghua University officially inaugurated the Tsinghua AI Agent Hospital during a ceremony attended by university leadership. This groundbreaking virtual healthcare platform represents the world's first AI-powered hospital system capable of autonomous clinical operations. The hospital integrates with Beijing Tsinghua Chang Gung Hospital and features AI doctors across multiple specialties to support personalized diagnostic and treatment services.
• June 2024: Merck, BeiGene, and Cornerstone Pharmaceutical announced plans to launch a precision diagnosis and treatment ecosystem targeting rare targets for lung cancer in China. The collaboration aims to jointly promote the high-quality development of precision medicines, increase the availability of products for cancers with rare molecular targets, and advance personalized treatment approaches in the Chinese oncology market.
• November 2024: Zijing Zhikang, a Tsinghua University spin-out startup, launched the "Zijing AI Doctor" system. Developed to serve as the core component in the AI Agent Hospital ecosystem, this system features 42 AI doctors across 21 clinical specialties, supporting personalized treatment plans and diagnostic services. The launch represents a significant advancement in China's efforts to deploy AI-driven personalized medicine at scale.

China Personalized Medicine Market Report Coverage:

Key Questions Answered in This Report:

• How has the China personalized medicine market performed so far and how will it perform in the coming years?
• What is the breakup of the China personalized medicine market on the basis of product?
• What is the breakup of the China personalized medicine market on the basis of end use?
• What is the breakup of the China personalized medicine market on the basis of region?
• What are the various stages in the value chain of the China personalized medicine market?
• What are the key driving factors and challenges in the China personalized medicine market?
• What is the structure of the China personalized medicine market and who are the key players?
• What is the degree of competition in the China personalized medicine market?

Key Benefits for Stakeholders:

• IMARC's industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the China personalized medicine market from 2020-2034.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the China personalized medicine market.
• Porter's five forces analysis assist stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the China personalized medicine industry and its attractiveness.
• Competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.